



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Travel Medicine and Infectious Disease

journal homepage: www.elsevier.com/locate/tmaid

Correspondence

SARS-CoV-2 variant from India to Marseille: The still active role of ports in the introduction of epidemics



ARTICLE INFO

Keywords

SARS-CoV-2

Covid

Indian variant

Port

Crew

Dear Editor,

A recent variant of SARS-CoV-2 named B.1.617 has spread to several countries from India [1]. The mutations found in the Indian variant in its spike are identified as E484Q, L452R, E154K and P681R. Amino acid 484 is changed in the South African variant B.1.351 and in the Brazilian variant P1 while L452R was already detected in a Californian variant. The association in a single variant of these mutations supposed to reduce recognition by antibodies and impact on attachment to the ACE2 receptor that has caused this strain to be classified as a variant of interest by the WHO due to a strong potential to cause epidemics [2].

We report herein the case of an Indian sailor coming to Marseille, south-east France, to embark as a crew member which illustrates the role of ports in the historical introduction of epidemics. This patient from Goa embarked at New Delhi airport, passed through Amsterdam airport and landed at Marseille airport on April 26, 2021. Tested SARS-CoV-2-negative 72 hours before boarding, he was detected positive upon arrival at Marseille by an antigen test. A new nasopharyngeal swab was performed for confirmation on April 27 and sent to our institute [3]. qRT-PCR was positive at Ct 17 and direct sequencing [4] confirmed the “Indian Variant” nature of this strain (Fig. 1, Supplementary Figure S1). On April 28, characteristic CPEs were seen in culture (Supplementary Figure S2) and the strain sub-cultured for subsequent sero-neutralization analysis on the sera of local patients carrying antibodies (vaccinated and convalescent). So far, five B.1.617 cases were documented in France ([https://www.nouvelle-aquitaine.ars.sante.fr/communiquede-presse-](https://www.nouvelle-aquitaine.ars.sante.fr/communiquede-presse-coronavirus-point-de-situation-en-nouvelle-aquitaine-au-30-avril-2021;https://solidarites-sante.gouv.fr/actualites/presse/communiqués-de-presse/article/premieres-detections-de-cas-de-contamination-au-variant-b-1-617-du-sars-cov-2)

[coronavirus-point-de-situation-en-nouvelle-aquitaine-au-30-avril-2021; https://solidarites-sante.gouv.fr/actualites/presse/communiqués-de-presse/article/premieres-detections-de-cas-de-contamination-au-variant-b-1-617-du-sars-cov-2](https://www.nouvelle-aquitaine.ars.sante.fr/communiquede-presse-coronavirus-point-de-situation-en-nouvelle-aquitaine-au-30-avril-2021;https://solidarites-sante.gouv.fr/actualites/presse/communiqués-de-presse/article/premieres-detections-de-cas-de-contamination-au-variant-b-1-617-du-sars-cov-2)).

This case perfectly illustrates the role played by ports such as Marseille in the entry of epidemics of distant origin. Indeed, for 2000 years this port has faced the arrival of epidemic agents, in particular plague, cholera, yellow fever. The history of these epidemics and the strategies put in place to fight them, including creation of our institute, have been recently reviewed [5]. For many years, merchant navy crews have mainly come from countries with low labor costs, in particular the Indian subcontinent, and the case of this sailor continues to illustrate this historical characteristic by the fact that it is an area of mixing of populations. It also raises the question of the lack of real control over transfers of people from areas where variants of concern are circulating. This patient had been tested before boarding and was able to transit unchecked to Marseille where, fortunately, civil security checks as many travelers as possible but without being exhaustive. It is very probable that similar situations will occur, illustrating the extreme difficulty of controlling the introduction of new epidemic variants in regions which are traditionally areas of intense transit. Ensuring effective detection of these cases is however critical, especially for crew members destined, as was the case with this sailor, to embark on cruise ships in order to avoid a repetition of the Diamond Princess episode [6].

<https://doi.org/10.1016/j.tmaid.2021.102085>

Received 4 May 2021; Received in revised form 7 May 2021; Accepted 12 May 2021

Available online 21 May 2021

1477-8939/© 2021 Elsevier Ltd. All rights reserved.




Fig. 1. Phylogeny reconstruction based on the SARS-CoV-2 full-length genomes.

The Marseille-IHU-9101 genome, indicated by a white bold font and a black background, is classified in Nextstrain clade 20A and Pangolin lineage B.1.617.2. It has been deposited in the GISAID database (<https://www.gisaid.org/>) [8] (No. EPI_ISL_1825677). Its best BLASTn hits ($n = 30$ selected) in GISAID have been obtained from samples collected recently (not earlier than the March 19, 2021) in India, Singapore, the USA, and Western Europe (England, Italy, Belgium, Germany, Greece). This genome is strongly clustered (bootstrap value, 100%) with these most similar sequences in a subcluster of lineage B.1.617.2, and is clustered (bootstrap value, 88%) with one sequence obtained from a sample collected in England the same day than the present case-patient.

The SARS-CoV-2 phylogenetic tree is based on the full-length SARS-CoV-2 genomes. The 30 sequences with the highest BLAST scores recovered from the GISAID database (<https://www.gisaid.org/>) [8] were incorporated in the phylogeny reconstruction, being indicated by a black bold font. Additional sequences included the genome of the Wuhan-Hu-1 isolate and genomes obtained in our institute and classified as predominant variants. Nucleotide alignments were performed using the MUSCLE software (<http://www.ebi.ac.uk/Tools/msa/muscle/>). Evolutionary history was inferred using the MEGAX software (<http://www.megasoftware.net/>) using the neighbor-joining method and the Kimura 2-parameter method. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next to the branches. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree; the scale bars indicate the number of nucleotide substitutions per site. Bootstrap values $> 50\%$ are indicated on the tree. Pangolin lineages determined using the Pangolin COVID-19 Lineage Assigner <https://pangolin.cog-uk.io/>) are indicated.

Acknowledgments

We are thankful to Emilie Burel for her technical help. This work was supported by the French Government under the « Investissements d'avenir » (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tmaid.2021.102085>.

Ethics

Data have been generated as part of the routine work at Assistance Publique-Hôpitaux de Marseille (Marseille university hospitals). This study has been approved by the ethics committee of our institution (N°2020-016-03) and written informed consent was obtained from the patient.

References

- [1] Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R. In: in the second wave of COVID-19 in Maharashtra, India. MedRxiv; 2021. <https://doi.org/10.1101/2021.04.22.440932>.
- [2] Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 2021;184:2348–61. <https://doi.org/10.1016/j.cell.2021.02.037>. e6.
- [3] Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: a respiratory virus snapshot. Trav Med Infect Dis 2020;36:101632. <https://doi.org/10.1016/j.tmaid.2020.101632>.
- [4] Colson P, Levasseur A, Gautret P, Fenollar F, Thuan Hoang V, Delerac J, et al. Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: an investigational study. Trav Med Infect Dis 2021;40:101980. <https://doi.org/10.1016/j.tmaid.2021.101980>.
- [5] Barbieri R, Colson P, Raoult D, Drancourt M. Two-millennia fighting against port-imported epidemics. Marseille: IHU Preprint; 2021. <https://doi.org/10.35088/84a4-me41>.
- [6] Yamagishi T, Kamiya H, Kakimoto K, Suzuki M, Wakita T. Descriptive study of COVID-19 outbreak among passengers and crew on Diamond Princess cruise ship, Yokohama Port, Japan, 20 January to 9 February 2020. Euro Surveill 2020;25. <https://doi.org/10.2807/1560-7917.ES.2020.25.23.2000272>. 2000272.

Bernard La Scola^{*}, Philippe Lavrard, Pierre-Edouard Fournier,
Philippe Colson
Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France
Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France

Alexandre Lacoste
Bataillon des Marins Pompiers de Marseille, Marseille, France

Didier Raoult
Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France
Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France

^{*} Corresponding author. IHU Méditerranée Infection, 19-21 Boulevard
Jean Moulin, 13005, Marseille, France.
E-mail address: bernard.la-scola@univ-amu.fr (B. La Scola).